Electromed, Inc.

Electromed, Inc.

AAMEX:ELMD
23.10
USD
-1.22
(-5.02%)
1.37EPS
19.56P/E
232.52MMarket Cap
Feb 16Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1.91
2.39
2.83
3.17
3.45
3.77
3.86
4.17
4.92
5.68
6.39
7.57
8.93
9.15
Basic EPS, GAAP
-0.16
0.13
0.27
0.27
0.22
0.24
0.5
0.28
0.27
0.37
0.6
0.89
1.37
1.44
Free Cash Flow per Basic Share
0.14
0.27
0.2
0.06
0.23
0.14
0.38
0.31
-0.08
0.16
1.06
1.35
1.17
1.19
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.57
1.71
2
2.32
2.73
3.06
3.53
3.8
4.03
4.4
5.16
5.18
6.45
6.37
Tangible Book Value per Share
1.44
1.59
1.89
2.23
2.65
2.99
3.46
3.72
3.96
4.33
5.08
5.02
6.27
6.18
Basic Weighted Avg Shares
8
8
8
8
8
8
8
9
8
8
9
8
8
8
Sales/Revenue/Turnover
15
19
23
26
28
31
32
36
42
48
55
64
74
76
Operating Margin (%)
-4.78
6.75
13.52
13.8
9.58
9.04
15.76
8.78
7.13
8.34
12.03
15.09
18.82
19.45
Depreciation Expense
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Net Income, GAAP
-1
1
2
2
2
2
4
2
2
3
5
8
11
12
Effective Tax Rate (%)
- -
10.78
27.28
36.65
32.98
32.19
20.58
25.42
23.09
22.52
26.81
26.71
21.3
21.5
Profit Margin (%)
-8.32
5.63
9.62
8.62
6.47
6.33
12.81
6.61
5.53
6.59
9.41
11.78
15.32
15.78
Working Capital
9
10
13
16
18
21
25
27
27
30
36
35
45
45
LT Debt
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
13
14
16
19
23
26
30
32
34
38
45
43
54
52
Return on Invested Capital (%)
- -
8
13.8
11.95
8.19
7.67
14.47
7.45
6.84
8.61
11.64
16.1
22.5
23.77
Return on Capital (%)
- -
8.01
13.87
12.03
8.34
8.01
14.86
7.54
6.92
8.81
12.53
17.18
23.26
24.53
Return on Common Equity (%)
-9.67
8.2
14.61
12.59
8.79
8.2
14.86
7.54
6.92
8.81
12.53
17.18
23.26
24.53

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
194
354
233

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
Total Current Assets
50
57
52
Cash, Cash Equivalents & STI
17
20
16
Accounts Receivable, Net
28
30
30
Inventories
3
4
4
Total Current Liabilities
10
12
7
Payables & Accruals
4
4
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.95%
11.17%
24.93%
Free Cash Flow
49.89%
36.44%
-15.17%
Net Income, GAAP
25.18%
38.78%
49.94%
Sales/Revenue/Turnover
12.43%
15.59%
15.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
15
16
16
17
64
2026
17
19
19
19
74
2027
19
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.17
0.23
0.22
0.26
0.89
2026
0.26
0.33
0.37
0.41
1.37
2027
0.33
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
James L. Cunniff
Full Time Employees
197
Sector
Health technology
Industry
Medical specialties
Address
500 Sixth Avenue NW New Prague MN United States 56071
IPO Date
Aug 13, 2010
Business
Electromed, Inc. develops, manufactures, markets, and sells medical devices that provide airway clearance therapy, primarily through its flagship product, the SmartVest Airway Clearance System. The SmartVest Systems utilize High Frequency Chest Wall Oscillation (HFCWO) technology to assist patients with compromised pulmonary function by facilitating mucus clearance. The company’s product portfolio includes the SmartVest SQL System, SmartVest Clearway System for inpatient hospital use, and single-patient-use SmartVest and SmartVest Wrap products. These devices are marketed to hospitals, home health care providers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and directly to patients, primarily in the United States, with distribution through both direct sales and home medical equipment distributors. Founded in 1992 and headquartered in New Prague, Minnesota, Electromed targets patients with chronic respiratory conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disorders. The company serves healthcare providers and patients by incorporating personalized therapy options, including recent expansions in SmartVest garment and generator color options to improve patient satisfaction and adherence. Recent major developments include Electromed’s strategic expansion of distribution channels via partnerships with national and regional home medical equipment distributors, enhancing access to the SmartVest in the U.S. home care market. In 2024, Electromed launched the SmartVest Clearway Airway Clearance System designed specifically for hospital inpatient use. The company also authorized a $10 million stock repurchase program in 2025, reflecting strong operational performance and robust cash reserves. Additionally, Electromed expanded access through a partnership in early 2024 aimed at veterans, federal employees, and Native American communities, advancing its mission to broaden patient reach. Electromed continues to focus on airway clearance innovation and market-driven solutions to support patients with chronic lung diseases, driving growth through product development, strategic partnerships, and expanded distribution while maintaining a strong market presence in the healthcare equipment and supplies sector.

Company News

  • Electromed, Inc. (ELMD) Q1 2027 Earnings Call Transcript

  • Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter

  • Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026

  • Cytosorbents (NASDAQ:CTSO) versus Electromed (NYSE:ELMD) Head to Head Comparison

  • Squarepoint Ops LLC Purchases Shares of 19,498 Electromed, Inc. $ELMD

  • Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event

  • Electromed: Contrarian 'Buy' With SmartVest

  • Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript

  • Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates

  • Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results

  • Electromed Announces CEO's Planned Retirement

  • Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026

  • 4 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, FLXS, ELMD & AGX

  • Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why

  • Here's Why Momentum in Electromed (ELMD) Should Keep going

  • Electromed: Strong Margins, Strong Growth, Large Runway

  • Is Electromed (ELMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

  • Best Momentum Stocks to Buy for June 2nd

  • New Strong Buy Stocks for June 2nd

  • Electromed, Inc. (ELMD) Hits Fresh High: Is There Still Room to Run?